Shares of Moderna were rising sharply in premarket trading Monday after the vaccine maker said a reformulated vaccine to tackle the Omicron variant could be ready in early 2022.
Moderna (ticker: MRNA) rose more than 9% to $359.80 in premarket trading Monday. The stock gained 20.6% on Friday after Moderna said it was working to rapidly advance an Omicron-specific booster candidate, targeting 60 to 90 days for clinical testing to begin.
“We…
